We are live on ! Find out more
RXRX icon

Recursion Pharmaceuticals

326 hedge funds and large institutions have $1.61B invested in Recursion Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 46 funds opening new positions, 135 increasing their positions, 75 reducing their positions, and 51 closing their positions.

New
Increased
Maintained
Reduced
Closed

121% more capital inflows, than outflows

Capital inflows: $187M | Capital outflows: $84.4M

80% more repeat investments, than reductions

Existing positions increased: 135 | Existing positions reduced: 75

70% more call options, than puts

Call options by funds: $52.4M | Put options by funds: $30.7M

0.52% less ownership

Funds ownership: 77.63% → 77.11% (-0.52%)

10% less first-time investments, than exits

New positions opened: 46 | Existing positions closed: 51

3% less funds holding

Funds holding: 335 → 326 (-9)

11% less funds holding in top 10

Funds holding in top 10: 9 → 8 (-1)

Holders
326
Holders Change
-9
Holders Change %
-2.69%
% of All Funds
4.25%
Holding in Top 10
8
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-11.11%
% of All Funds
0.1%
New
46
Increased
135
Reduced
75
Closed
51
Calls
$52.4M
Puts
$30.7M
Net Calls
+$21.7M
Net Calls Change
+$7.03M

RXRX Hedge Fund Activity: Q3 2025 in Review

326 of the 7,664 institutional investors tracked by Wall St. Rank reported a position in Recursion Pharmaceuticals (RXRX) for Q3 2025, worth a combined $1.61B — up 2.4% from $1.57B a quarter earlier.

Sellers outnumbered buyers: 51 funds closed out of RXRX and 46 opened new positions — a net loss of 5 holders — while 75 trimmed existing stakes and 135 added.

The largest buyer was State Street, adding an estimated $37.2M. The largest seller was Fidelity Investments, cutting an estimated $12.4M.

  • 326 institutional investors held Recursion Pharmaceuticals (RXRX) as of Q3 2025, down from 335 in Q2 2025.
  • Funds reported $1.61B of Recursion Pharmaceuticals stock for Q3 2025, up 2.4% quarter-over-quarter.
  • 46 funds opened new Recursion Pharmaceuticals positions in Q3 2025 and 51 closed out, a net change of -5 holders.
  • The largest Recursion Pharmaceuticals buyer in Q3 2025 was State Street, an estimated $37.2M added.
  • The largest Recursion Pharmaceuticals seller in Q3 2025 was Fidelity Investments, an estimated $12.4M sold.

Based on aggregated 13F filings for Q3 2025.